Cited by 328Hormonal and reproductive studiesHypothalamic control of reproductive hormonesAdrenal Hormones and Disorders

Male hypogonadism

Basaria, Shehzad·2014·The Lancet

Abstract

Male hypogonadism is a clinical syndrome that results from failure to produce physiological concentrations of testosterone, normal amounts of sperm, or both. Hypogonadism may arise from testicular disease (primary hypogonadism) or dysfunction of the hypothalamic-pituitary unit (secondary hypogonadism). Clinical presentations vary dependent on the time of onset of androgen deficiency, whether the defect is in testosterone production or spermatogenesis, associated genetic factors, or history of androgen therapy. The clinical diagnosis of hypogonadism is made on the basis of signs and symptoms consistent with androgen deficiency and low morning testosterone concentrations in serum on multiple occasions. Several testosterone-replacement therapies are approved for treatment and should be selected according to the patient's preference, cost, availability, and formulation-specific properties. Contraindications to testosterone-replacement therapy include prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract symptoms, and erythrocytosis. Treatment should be monitored for benefits and adverse effects.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)61126-5

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevated follicle-stimulating hormone levels in the setting of testosterone deficiency (hypergonadotropic hypogonadism) are typically indicative of impaired spermatogenesis.

    “Elevated follicle-stimulating hormone levels in the setting of testosterone deficiency (hypergonadatropic hypogonadism) is typically indicative of impaired spermatogenesis”
  • Androgens are needed during the male life span to promote masculine development/virilization and growth, and are of vital importance in reproductive functioning.

    “These androgens are, during the male life span, needed to promote masculine development/virilization and growth, and are of vital importance in reproductive functioning [166].”
  • Symptoms of androgen deficiency vary according to age of onset, severity of T deficiency, androgen sensitivity and previous and/or current use of T replacement therapy.

    “Manifesting differently between male individuals, symptoms of androgen deficiency vary according to age of onset, severity of T deficiency, androgen sensitivity and previous and/or current use of T replacement therapy [166].”

Cites

Flagged first, then by citations

2 of the 146 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Basaria, S.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Basaria, Shehzad
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-04
Volume
383
Issue
9924
Pages
1250-1263
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4211201846
Cited by
328
References
146
Citations by year
2026: 24 · 2025: 30 · 2024: 38 · 2023: 33 · 2022: 45 · 2021: 30 · 2020: 33 · 2019: 18 · 2018: 19 · 2017: 17 · 2016: 17 · 2015: 14 · 2014: 9 · 2013: 1
FWCI
2.01
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
male hypogonadism, androgen deficiency, hypergonadotropic hypogonadism, secondary hypogonadism, testosterone replacement therapy, spermatogenesis, hypothalamic-pituitary dysfunction, testicular diseases, diagnosis, treatment monitoring, contraindications
MeSH terms
Contraindications, Administration, Cutaneous, Administration, Oral, Affect, Androgens, Cardiovascular Diseases, Cognition Disorders, Diabetes Mellitus, Gels, Humans, Hypogonadism, Hypothalamo-Hypophyseal System, Insulin Resistance, Lipids, Male, Polycythemia, Prostatic Neoplasms, Quality of Life, Sexual Dysfunction, Physiological, Sleep Apnea Syndromes, Tablets, Testis, Testosterone, Bone Density, Patient Satisfaction, Early Diagnosis, Muscle Strength

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review